U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H25ClFN5O3.2C4H4O4
Molecular Weight 706.0732
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 2
Charge 0

SHOW SMILES / InChI
Structure of SAPITINIB DIFUMURATE

SMILES

CN=C(CN1CCC(CC1)Oc2cc3c(cc2OC)ncnc3Nc4cccc(c4F)Cl)O.C(\[H])(=C(/[H])\C(=O)O)/C(=O)O.C(\[H])(=C(/[H])\C(=O)O)/C(=O)O

InChI

InChIKey=LSXKPHWAKWZIKV-LVEZLNDCSA-N
InChI=1S/C23H25ClFN5O3.2C4H4O4/c1-26-21(31)12-30-8-6-14(7-9-30)33-20-10-15-18(11-19(20)32-2)27-13-28-23(15)29-17-5-3-4-16(24)22(17)25;2*5-3(6)1-2-4(7)8/h3-5,10-11,13-14H,6-9,12H2,1-2H3,(H,26,31)(H,27,28,29);2*1-2H,(H,5,6)(H,7,8)/b;2*2-1+

HIDE SMILES / InChI

Molecular Formula C23H25ClFN5O3
Molecular Weight 473.9285
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H4O4
Molecular Weight 116.0723
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Sapitinib is an oral, reversible and equipotent inhibitor of EGFR, HER2 and HER3 signalling. The drug was tested in phase II of clinical trials in patients with breast cancer, colorectal cancer, gastric cancer and NSCL carcinoma, however its development for breast cancer therapy seems to be terminated. Sapitinib absorption is rapid and the drug is totally cleared by metabolism with the major routes being oxidation and amine or ether cleavage around the piperidine ring with subsequent glucuronide or sulphate conjugation.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.
2013 Aug 8

Sample Use Guides

Colorectal cancer: Patients were receiving 160 mg sapitinib tablets, twice daily on days 1-4 of each 2-weekly cycle + FOLFIRI. Breast cancer: Patients were receiving daily anastrozole (1 mg) in combination with sapitinib 20 mg twice daily (bid) or sapitinib 40 mg bid.
Route of Administration: Oral
MCF7 and T47D breast cancer cells were treated with sapitinib (1 uM) in combination with estradiol (10−9 M), estrogen deprivation, tamoxifen (10−7 M), or ICI 182,78 (10−7 M).
Substance Class Chemical
Created
by admin
on Sat Jun 26 08:39:25 UTC 2021
Edited
by admin
on Sat Jun 26 08:39:25 UTC 2021
Record UNII
RD1QAE9R4N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SAPITINIB DIFUMURATE
Common Name English
1-PIPERIDINEACETAMIDE, 4-((4-((3-CHLORO-2-FLUOROPHENYL)AMINO)-7-METHOXY-6-QUINAZOLINYL)OXY)-N-METHYL-, (2E)-2-BUTENEDIOATE (1:2)
Systematic Name English
AZD8931 DIFUMARICACID
Code English
AZD-8931 DIFUMARICACID
Common Name English
Code System Code Type Description
CAS
1196531-39-1
Created by admin on Sat Jun 26 08:39:25 UTC 2021 , Edited by admin on Sat Jun 26 08:39:25 UTC 2021
PRIMARY
FDA UNII
RD1QAE9R4N
Created by admin on Sat Jun 26 08:39:25 UTC 2021 , Edited by admin on Sat Jun 26 08:39:25 UTC 2021
PRIMARY
PUBCHEM
44470103
Created by admin on Sat Jun 26 08:39:25 UTC 2021 , Edited by admin on Sat Jun 26 08:39:25 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY